US FDA Approves Baricitinib: EMRO Recognized For Their Participation

May 20, 2022 by

Slide showing UVA Health announcement of EMRO's participation in the ACTT-2 Trial and US FDA's approval of baricitinib for treatment of hospitilized COVID-19 patients
EMRO contributed their hard work and data towards the ACTT-2 Trial. Their participation, as well as others who contributed, resulted in the May 11, 2022 announcement that the US FDA has given full approval of baricitinib as a treatment for hospitalized patients with COVID-19.